Medico Remedies Limited share price
Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as antihypertensive, antidiabetics, antibiotics diuretics, and antiretrovirals. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.Read more
- Market Cap₹ 183 Cr.
- Current Price₹ 22.03
- High / Low₹ 57 / 20
- Stock P/E13.2
- Book Value₹ 9
- Dividend Yield0.00 %
- ROCE25.1 %
- ROE19.00 %
- Face Value₹ 2.0
More figures (10)
- EPS (TTM)₹ 1.67
- Price / Book2.41
- OPM6.8 %
- Debt / Equity0.26
- Sales growth (3Y)13.7 %
- Profit growth (3Y)21.9 %
- Promoter holding68.2 %
- EV / EBITDA11.3
- Beta0.71
- All-time high₹ 101
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| MEDICO | -37.65% | -43.32% | -44.40% | -56.46% | -54.08% | -32.26% | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Medico Remedies Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹183 crore.
- It trades at 13.2 times its last 12 months' earnings and 2.4 times book value.
- Revenue grew 13.7% a year over the last 3 years, profit 21.9% a year.
- Return on equity was 19.0% and return on capital employed 25.1% in the latest year.
- Debt was 0.26 times shareholders' equity.
- The share price is 61.3% below its 52-week high and down 54.1% over one year.
- Promoters and insiders hold about 68.2%; institutions about 0.0%.
Pros
AI- Profit has grown 21.9% a year over the last 3 years.
- Latest quarter (Jun 2026): sales up 81% and profit up 38% from a year ago.
- Healthy return on equity of 17.9% on average over the last 3 years.
- Trades at 13.2 times earnings, below its 3-year median of 48.5.
- Borrowings are moderate at 0.26 times shareholders' equity.
Cons
AI- Promoter holding has fallen by 11.96 points over 3 years, to 61.38%.
- Other income makes up 34% of profit before tax.
- The company has not paid a dividend recently.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Medico Remedies Limited
Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as antihypertensive, antidiabetics, antibiotics diuretics, and antiretrovirals. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.
- Employees
- 105
- Head office
- Mumbai
Peer comparison
HealthcareDrug Manufacturers - Specialty & Generic
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Medico Remedies | 22.03 | 13.2 | 183 | 0.00 | 3 | 38.49 | 69 | 81.43 | 25.1 | 19.0 | 2.41 | 6.8 | 0.26 | 68.21 | 206 | 13.7 |
| 2. | Sun Pharmaceutical Industries | 1,758.80 | 34.9 | 4,21,995 | 0.91 | 2,895 | 34.65 | 15,184 | 18.48 | 17.9 | 14.7 | 5.05 | 23.4 | 0.06 | 55.61 | 58,220 | 10.4 |
| 3. | Divi's Laboratories | 9,144.50 | 83.0 | 2,42,758 | 0.33 | 902 | 36.25 | 3,080 | 19.15 | 19.0 | 16.2 | 14.48 | 28.4 | 0.00 | 52.00 | 10,476 | 11.0 |
| 4. | Torrent Pharmaceuticals | 4,558.90 | 72.8 | 1,73,406 | 0.83 | 566 | 3.28 | 4,921 | 54.85 | 9.1 | 27.1 | 18.39 | 25.0 | 1.79 | 63.18 | 13,980 | 13.3 |
| 5. | Zydus Lifesciences | 1,123.00 | 25.0 | 1,12,020 | 0.09 | 940 | -19.74 | 7,802 | 24.03 | 19.0 | 19.7 | 4.17 | 21.7 | 0.46 | 75.18 | 26,720 | 16.5 |
| 6. | Laurus Labs | 2,060.10 | 101.8 | 1,11,310 | 0.12 | 362 | 123.94 | 2,026 | 29.10 | 19.5 | 18.2 | 20.98 | 19.4 | 0.48 | 32.03 | 6,813 | 3.8 |
| 7. | Cipla | 1,325.10 | 31.8 | 1,07,051 | 0.98 | 786 | -39.18 | 7,119 | 2.33 | 14.9 | 11.8 | 3.11 | 17.5 | 0.02 | 31.13 | 28,163 | 7.2 |
| 8. | Dr. Reddy's Laboratories | 1,233.00 | 31.0 | 1,02,707 | 0.66 | 444 | -68.72 | 8,071 | -5.56 | 14.2 | 12.1 | 2.68 | 14.9 | 0.21 | 30.14 | 33,593 | 11.0 |
| 9. | Aurobindo Pharma | 1,666.90 | 26.0 | 95,910 | 0.00 | 1,033 | 14.29 | 9,106 | 8.65 | 13.5 | 9.9 | 2.56 | 15.6 | 0.21 | 54.79 | 33,385 | 10.7 |
| 10. | Mankind Pharma | 2,275.50 | 46.0 | 93,988 | 0.00 | 574 | 29.12 | 4,031 | 12.89 | 13.7 | 12.5 | 5.76 | 19.9 | 0.39 | 75.39 | 14,278 | 17.7 |
| Median: 61 Co. | 1,712.85 | 34.1 | 11,199 | 0.17 | 680 | 21.70 | 6,020 | 18.81 | 16.4 | 13.2 | 3.86 | 15.1 | 0.24 | 55.20 | 20,499 | 11.4 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
Standalone figures in ₹ crore
Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.
Profit & Loss
Standalone figures in ₹ crore
Projection — your assumptions
Starts from the last four reported quarters (TTM) and applies the figures you enter; growth is pre-filled with the company's own 3-year sales growth. This is a what-if calculator for illustration, not a forecast, estimate or recommendation.
Related party transactions
Related-party transactions are dealings with promoters, directors, subsidiaries and associates. Companies disclose them to the exchanges every half-year and in detail in the notes to their annual report.
- Related Party TransactionsMedico Remedies Limited has informed the Exchange about related Party Transactions11-May-2023
- Related Party TransactionMedico Remedies Limited has informed the Exchange about related party transaction for the period ended September 202214-Nov-2022
- Related Party TransactionMedico Remedies Limited has informed the Exchange about related party transaction for the period ended March 2022 as per new format16-Aug-2022
Full details: notes to the Financial Year 2026 annual report (related party disclosures).
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| 140 | 145 | 151 | 206 | 238 | |
| YOY Sales Growth % | 3.19% | 4.15% | 36.73% | ||
| 131 | 132 | 136 | 189 | 220 | |
| Material Cost % | 75% | 76% | 72% | 73% | 76% |
| Employee Cost % | 4% | 4% | 4% | 4% | 3% |
| Other Expenses % | 14% | 11% | 14% | 15% | 14% |
| Operating Profit | 10 | 13 | 15 | 17 | 18 |
| OPM % | 7% | 9% | 10% | 8% | 7% |
| Other Income | 4 | 2 | 3 | 6 | 6 |
| Interest | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 10 | 11 | 14 | 18 | 19 |
| 28% | 27% | 25% | 27% | 27% | |
| Current tax | 2 | 3 | 4 | 5 | |
| Deferred tax | 0 | -0 | -0 | -0 | |
| 7 | 8 | 10 | 13 | 14 | |
| YOY Profit Growth % | 14.49% | 21.74% | 29.94% | ||
| EPS in Rs | 0.09 | 1.00 | 1.22 | 1.58 | 2.02 |
Compounded Sales Growth
- 3 Years:
- 14%
- TTM:
- 50%
Compounded Profit Growth
- 3 Years:
- 22%
- TTM:
- 34%
Stock Price CAGR
- 3 Years:
- -32%
- 1 Year:
- -54%
Return on Equity
- 4 Years:
- 18%
- Last Year:
- 19%
Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 17 | 17 | 17 | 17 |
| Reserves | 27 | 36 | 46 | 59 |
| 10 | 8 | 15 | 19 | |
| Long term borrowings | 0 | |||
| Short term borrowings | 8 | 7 | 14 | 19 |
| 34 | 36 | 43 | 59 | |
| Trade payables | 31 | 32 | 35 | 49 |
| Current liabilities | 42 | 43 | 57 | 78 |
| Total Liabilities | 87 | 96 | 120 | 153 |
| 22 | 21 | 22 | 23 | |
| Gross block | 39 | 41 | 43 | 47 |
| Accumulated depreciation | 18 | 20 | 21 | 24 |
| Goodwill & intangibles | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 3 |
| 66 | 75 | 98 | 128 | |
| Inventories | 20 | 16 | 27 | 30 |
| Trade receivables | 36 | 50 | 57 | 82 |
| Cash & equivalents | 1 | 0 | 1 | 2 |
| Current assets | 65 | 74 | 97 | 129 |
| Total Assets | 87 | 96 | 120 | 153 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 8 | 2 | 5 | 6 | |
| Profit for the year | 7 | 8 | 10 | 13 |
| Working capital changes | -2 | -9 | -7 | -10 |
| Direct taxes paid | -2 | -3 | -4 | -5 |
| -7 | -3 | -3 | -5 | |
| Fixed assets purchased | -7 | -2 | -3 | -4 |
| Fixed assets sold | 0 | 0 | 0 | 0 |
| Investments purchased | -0 | -0 | -0 | -0 |
| Investments sold | 0 | 0 | ||
| -2 | -0 | -1 | -1 | |
| Repayment of borrowings | -1 | |||
| Interest paid | -0 | |||
| Net Cash Flow | -0 | -1 | 1 | 1 |
| Free Cash Flow | 2 | -0 | 2 | 1 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | 16.5% | 17.2% | 17.6% | 19.0% |
| ROCE | — | 23.4% | 22.4% | 22.8% | 25.1% |
| Operating margin | — | 5.0% | 7.0% | 8.1% | 6.8% |
| Net margin | — | 5.2% | 5.8% | 6.8% | 6.4% |
| Debt / equity | — | 0.22 | 0.15 | 0.24 | 0.26 |
| Current ratio | — | 1.55 | 1.72 | 1.70 | 1.66 |
| Debtor days | — | 95 | 126 | 140 | 147 |
| Inventory days | — | 64 | 50 | 82 | 66 |
| Days payable | — | 100 | 97 | 106 | 108 |
| Cash conversion cycle | — | 59 | 79 | 116 | 105 |
| Working capital days | — | 60 | 79 | 98 | 92 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- Promoters 61.38%
- FIIs 0.60%
- Public 38.02%
| % | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 73.34% | 73.34% | 73.34% | 73.34% | 66.83% | 63.79% | 62.59% | 61.38% | 61.38% | 61.38% | 61.38% | 61.38% |
| 1.29% | 0.29% | 0.23% | 0.22% | 0.39% | 0.12% | 0.07% | 0.30% | 0.49% | 0.03% | 0.08% | 0.60% | |
| Foreign portfolio investors (Cat. I) | 0.09% | 0.07% | 0.04% | 0.04% | 0.07% | 0.30% | 0.49% | 0.03% | 0.08% | 0.22% | ||
| Foreign portfolio investors (Cat. II) | 1.20% | 0.22% | 0.22% | 0.35% | 0.07% | 0.38% | ||||||
| 0.74% | 0.97% | 0.97% | 0.78% | 0.01% | 0.01% | 0.01% | ||||||
| Alternative investment funds | 0.74% | 0.97% | 0.97% | 0.78% | 0.01% | 0.01% | 0.01% | |||||
| 25.37% | 25.63% | 25.47% | 25.47% | 32.00% | 36.08% | 37.33% | 38.30% | 38.13% | 38.59% | 38.54% | 38.02% | |
| Retail (up to ₹2 lakh) | 6.75% | 8.06% | 10.71% | 10.73% | 13.08% | 13.52% | 14.60% | 14.86% | 14.71% | 14.82% | 15.16% | 18.80% |
| HNIs (above ₹2 lakh) | 7.89% | 6.33% | 6.78% | 6.93% | 5.00% | 8.61% | 8.20% | 8.25% | 8.01% | 8.74% | 8.52% | 5.97% |
| NRIs | 0.17% | 0.25% | 0.24% | 0.25% | 0.35% | 0.37% | 0.32% | 0.42% | 0.58% | 0.61% | 0.58% | 0.53% |
| Bodies corporate | 7.66% | 6.29% | 2.14% | 2.04% | 4.59% | 4.62% | 4.76% | 5.45% | 5.42% | 4.81% | 4.72% | 4.06% |
| No. of Shareholders | 6,052 | 10,685 | 12,902 | 12,887 | 14,104 | 15,424 | 16,474 | 18,503 | 16,562 | 16,189 | 15,863 | 17,716 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Documents
Announcements
- Price movementSignificant movement in price has been observed in Medico Remedies Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and …29-Sep-2026
- Trading WindowMedico Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201529-Sep-2026
- Shareholders meetingMedico Remedies Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 22, 2026. Further, the company has informed the Exchange r…23-Sep-2026
- Shareholders meetingMedico Remedies Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 22, 202622-Sep-2026
- General UpdatesMedico Remedies Limited has informed the Exchange about Book Closure Dates.29-Aug-2026
- Shareholders meetingMedico Remedies Limited has informed the Exchange regarding Notice of undefined to be held on September 22, 202629-Aug-2026
- Outcome of Board MeetingMedico Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.13-Aug-2026
- Bagging/Receiving of orders/contractsMedico Remedies Limited has informed the Exchange about Bagging/Receiving of orders/contracts05-Aug-2026
- Trading WindowMedico Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201530-Jun-2026
- Action(s) taken or orders passedMedico Remedies Limited has informed the Exchange about Action(s) taken or orders passed03-Jun-2026
- Disclosure under SEBI Takeover Regulations Harshit Mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeo…01-Jun-2026
- Outcome of Board MeetingMedico Remedies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.21-May-2026
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 1 Jan 1970
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
No recent coverage found.
From the company (NSE)
- Price movementSignificant movement in price has been observed in Medico Remedies Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and …NSE filing · 29-Sep-2026
- Trading WindowMedico Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015NSE filing · 29-Sep-2026
- Shareholders meetingMedico Remedies Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 22, 2026. Further, the company has informed the Exchange r…NSE filing · 23-Sep-2026
- Shareholders meetingMedico Remedies Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 22, 2026NSE filing · 22-Sep-2026
- General UpdatesMedico Remedies Limited has informed the Exchange about Book Closure Dates.NSE filing · 29-Aug-2026
- Shareholders meetingMedico Remedies Limited has informed the Exchange regarding Notice of undefined to be held on September 22, 2026NSE filing · 29-Aug-2026
- Outcome of Board MeetingMedico Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.NSE filing · 13-Aug-2026
- Bagging/Receiving of orders/contractsMedico Remedies Limited has informed the Exchange about Bagging/Receiving of orders/contractsNSE filing · 05-Aug-2026
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Medico Remedies Limited
What is the share price of Medico Remedies Limited today?
What is the market cap of Medico Remedies Limited?
What is the P/E ratio of Medico Remedies Limited?
Is Medico Remedies Limited a good investment?
How can I buy Medico Remedies Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.